

Anno	Tipologia	Titolo Progetto	Proponente	Finanziato	Inizio	Scadenza	Finanziamento	Co-finanziamento
2025	PRID	LSD for Nicotine Dependence and Comorbidities: Uncovering Neurobiological Mechanisms and Therapeutic Feasibility in a Preclinical Model	Comai Stefano	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	Monoamine oxidase inhibitors to hit a key player in neuroinflammation associated with neurodegenerative diseases	Dalla Via Lisa	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	Ultrasmall Copper Clusters as Tumor-selective Catalyst for Enhanced Chemodynamic Therapy and Radiotherapy	Gandin Valentina	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	From Binding to Function: Identification and Optimization of CXC-type chemokine receptor 4 (CXCR4) Agonists for Neuromuscular Junction Regeneration in Amyotrophic Lateral Sclerosis (ALS) Therapy	Mattarei Andrea	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	Peridroplet Mitochondria: Key Players in Cisplatin Resistance of Gynecological Cancers	Montopoli Monica	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	Development of a structural mass spectrometry-based assay to detect human transthyretin aggregates in the plasma of ATTR amyloidosis patients	Spolaore Barbara	sì	18/12/2025	31/12/2027	28.000 €	--
2025	PRID	Looking outside the gut-brain axis: is liver a novel player in AD and PD?	Colucci Rocchina	no				--
2024	PRID	Do novel dual COX-2 inhibitors/TP receptor antagonists regulate the immune response in the tumor inflammatory microenvironment?	Bolego Chiara	sì	17/12/2024	31/12/2026	25.000 €	--
2024	PRID	EngineerINg systems To countERact inFluEnza viRal infEctions (INTERFERE)	Morpurgo Margherita	sì	17/12/2024	31/12/2026	25.000 €	--
2024	PRID	Senescent cells and their secretory phenotype as targets for aging related-diseases therapy	Montopoli Monica	no				--
2023	PRID	3D Melanoma co-cultures as improved models for delivering immunotherapies towards advanced melanomas	Garofalo Mariangela	sì	23/11/2023	31/12/2025	30.000 €	--
2023	PRID	Myelin and gut during early life: potential partners in crime in gender-related neuropsychiatric disorders (MINDINGUT)	Giron Cecilia	sì	23/11/2023	31/12/2025	30.000 €	--
2023	PRID	Exploiting Mannose Receptor-blockers to prevent and treat metaflammation	Mastrotto Francesca	sì	23/11/2023	31/12/2025	30.000 €	--
2023	PRID	Liposomes loaded with Prodrugs of SYK Inhibitors (PSYKIs) for the treatment of NASH and NASH-HCC	Chilin Adriana	no				--
2023	PRID	Amylothrombosis: Investigating the effect of pathogenic amyloid fibrils in the activation of blood coagulation	De Filippis Vincenzo	no				--
2023	PRID	Circadian Rhythms and mitochondrial alterations: innovative perspectives in cisplatin-resistant ovarian cancer	Montopoli Monica	no				--
2022	PRID	Theranostic Copper Complexes in Prostate Cancer (THERACuPROST)	Marzano Cristina	sì	15/12/2022	14/12/2024	30.000 €	--
2022	PRID	Interplay between alpha-synuclein, lipid membrane and an amyloid inhibitor: a tripartite system against the progression of Parkinson disease	Polverino de Laureto Patrizia	sì	15/12/2022	14/12/2024	30.000 €	--
2022	PRID	Smaller is Better: expanding the chemical space sampling in fragment screening by using ultra low molecular weight compounds and NMR	Sturlese Mattia	sì	15/12/2022	14/12/2024	30.000 €	--
2022	PRID	Novel mannose receptor-targeted synthetic polysaccharides for the treatment of arthritis	Zusso Morena	sì	15/12/2022	14/12/2024	30.000 €	--
2022	PRID	Exploiting Mannose Receptor-blockers to treat metaflammation	Mastrotto Francesca	no				--
2022	PRID	Therapeutic monoclonal antibodies: real-life stability and photostability	Miolo Giorgia	no				--

Anno	Tipologia	Titolo Progetto	Proponente	Finanziato	Inizio	Scadenza	Finanziamento	Co-finanziamento
2021	PRID	NLRP3 inflammasome in Parkinson's disease: pharmacological modulation and impact of high fat diet on central and peripheral inflammatory processes	Colucci Rocchina	sì	16/12/2021	15/12/2023	30.000 €	--
2021	PRID	New agents for multifaceted targeting of neurodegenerative diseases	Dalla Via Lisa	sì	16/12/2021	15/12/2023	30.000 €	--
2021	PRID	Development of small Molecules for the EGFR-ECD Targeting (MEETs): a new strategy for the early in vivo diagnosis of EGFR-overexpressing cancers	Marzaro Giovanni	sì	16/12/2021	15/12/2023	30.000 €	--
2021	PRID	MOdulation of Copper TRansport in ANticaner Strategies (MOCTRANS)	Dolmella Alessandro	no				--
2021	PRID	Multiple sclerosis and TOLL-like rEceptor 4 signAling: linking eNteriC dysfunction to nEurodegeneration (TOLLERANCE)	Giron Maria Cecilia	no				--
2021	PRID	Interfering in the amyloid fibril formation against the progression of Parkinson disease (InterPD)	Polverino de Laureto Patrizia	no				--
2020	PRID	"Smart extraction chains" with green approaches. Active fractions and isolated compounds from timber waste for pharmaceutical, nutraceuticals, cosmetic uses	Dall'Acqua Stefano	sì	22/12/2020	21/12/2022	30.000 €	--
2020	PRID	Mitochondrial targeting as a novel strategy to overcome osteosarcoma chemoresistance	Ragazzi Eugenio	sì	22/12/2020	21/12/2022	30.000 €	--
2020	PRID	Role of tryptophan metabolism in experimental models of impaired microbiota-gut-brain axis	Bertazzo Antonella	no				--
2020	PRID	Impact of high fat diet in central and peripheral inflammatory processes in Parkinson disease: role of multiproteic complex NLRP3 inflammosome	Colucci Rocchina	no				--
2020	PRID	MULTIpurpose COpper-based approach to COlon cAnceR therapy through EXploitation of hCTR1-mediated high affinity transPORT (MULTI_COCOA_EXPORT)	Dolmella Alessandro	no				--
2020	PRID	Natural compounds and related synthetic derivatives as inhibitors of alpha-glucosidase, LDL oxidation and protein glycation searching for new agents useful in peripheral arterial disease	Froldi Guglielmina	no				--
2020	PRID	Investigation on the photostability of cannabinoids and of novel psychoactive substances in seized products and in hair samples	Miolo Giorgia	no				--
2019	PRID	Interaction between intermediate filament proteins and G-rich oncogene promoters: a novel perspective to control gene expression	Sissi Claudia	sì	12/11/2019	11/11/2021	32.000 €	8.000 €
2019	PRID	Development of novel anti-HER2 targeted ananas formulations for treating HER2+ breast cancer	Morpurgo Margherita	sì	12/11/2019	11/11/2021	32.000 €	8.000 €
2019	PRID	Targeting CCK2R for the delivery of radiopharmaceuticals in the treatment of solid tumors	Realdon Nicola	sì	12/11/2019	11/11/2021	32.000 €	8.000 €
2019	PRID	Unravelling the crosstalk between liver immunology and oxidative stress: a novel paradigm in hepatic fibrosis	De Martin Sara	sì	12/11/2019	11/11/2021	32.000 €	8.000 €
2019	PRID	Investigation on the photostability of cannabinoids and of novel psychoactive substances in seized products and hair samples	Miolo Giorgia	no				
2019	PRID	Deliverable multivalent metal-based theranostic drugs	Dolmella Alessandro	no				
2019	PRID	Natural polyphenolic compounds and related synthetic derivatives against alpha-glucosidase and protein glycation to obtain new agents for peripheral artery disease	Froldi Guglielmina	no				
2019	PRID	Novel pathogenetic mechanisms in thrombotic and amyloidotic diseases	De Filippis Vincenzo	RITIRATO				

Anno	Tipologia	Titolo Progetto	Proponente	Finanziato	Inizio	Scadenza	Finanziamento	Co-finanziamento
2018	PRID	Identification of novel functional and molecular targets for cardiac glycosides beyond the heart Na/K ATPase: focus on estrogen-dependent cancer inflammatory microenvironment	Bolego Chiara	sì	06/11/2018	05/11/2020	32.000 €	8.000 €
2018	PRID	Preclinical characterization of new TMA analogues as CFTR modulators	Chilin Adriana	Sì	06/11/2018	05/11/2020	32.000 €	8.000 €
2018	PRID	Molecular mechanisms involved in musculoskeletal disorders in oncological patients treated with tamoxifen: basis to develop promising treatments to prevent disability and improve quality of life	Montopoli Monica	sì	06/11/2018	05/11/2020	32.000 €	8.000 €
2018	PRID	Application of hydrogen exchange mass spectrometry in molecular medicine - Probing protein structure and dynamics in protein systems of biopharmaceutical interest	Spolaore Barbara	sì	06/11/2018	05/11/2020	32.000 €	8.000 €
2018	PRID	Novel curcumin analogues as inhibitors of amyloid β -induced neuroinflammation in Alzheimer's disease	Zusso Morena	sì	06/11/2018	05/11/2020	32.000 €	8.000 €
2017	PRID	Insight into the inhibition mechanism of α -synuclein aggregation by oleuropein aglycone: a structural point of view	Polverino de Laureto Patrizia	sì	01/01/2018	31/12/2019	32.000 €	8.000 €
2017	PRID	Exploring the neuroimmune crosstalk in inflammatory bowel diseases	Giron Maria Cecilia	sì	01/01/2018	31/12/2019	32.000 €	8.000 €
2017	PRID	An in depth investigation on novel Pt-based agents to shed light on cancer resistance mechanisms	Dalla Via Lisa	sì	01/01/2018	31/12/2019	32.000 €	8.000 €
2017	PRID	Nucleic Acids alkylation by bis-chloropiperdines: nanotech empowered therapy in cancer cells	Gatto Barbara	sì	01/01/2018	31/12/2019	32.000 €	8.000 €
2017	PRID	Novel TMA analogues for rescue and potentiation of defective CFTR	Chilin Adriana	no				
2017	PRID	Cross-talk between lipid droplets and autophagosomes in cisplatin-resistant cells	Montopoli Monica	no				
2017	PRID	STARS - Synthesis of triggered ananas release systems: a smart strategy against autoimmune liver diseases (ALD)	Zagotto Giuseppe	no				
2016	PRID	Maternal obesity and high-fat diet in childhood: study of the molecular mechanisms underlying gastrointestinal and cardiovascular disorders	Colucci Rocchina	sì	01/01/2017	31/12/2018	32.000 €	8.000 €
2016	PRID	Investigating the relationship between PCSK9 and chronic inflammation associated with obesity and insulin resistance	Ferri Nicola	sì	01/01/2017	31/12/2018	32.000 €	8.000 €
2016	PRID	New selective class III receptor tyrosine kinase inhibitors for cancer treatment	Marzaro Giovanni	sì	01/01/2017	31/12/2018	32.000 €	8.000 €
2016	PRID	Enteric nervous system and dendritic cells: two players in tolerance failure in celiac disease?	Di Liddo Rosa	sì	01/01/2017	31/12/2018	32.000 €	8.000 €
2016	PRID	Development of a metabolomics-based platform for the evaluation of nutraceutical role in ageing in mice	Dall'Acqua Stefano	sì	01/01/2017	31/12/2018	32.000 €	8.000 €
2016	PRID	Bioactive and dual self-assembling compounds: novel strategies to fight breast cancer	Dalla Via Lisa	no				
2016	PRID	Development of biocompatible polymers for StereoLythogrAphy (SLA) bioprinting for controlled manufacturing of 3D cell spheroids dedicated to drug formulation testings	Morpurgo Margherita	no				
2016	PRID	Wild plants as pharmaceutical and food resources: the glucosinolate/myrosinase system in crambe tataria and its unexploited potential	Piovan Anna	no				
2016	PRID	A Natural Compound from Olive Oil As Potential Inhibitor Of α -Synuclein Aggregation	Polverino de Laureto Patrizia	no				

ASSEGNAZIONI SID 2016-2024

Anno	Tipologia	Titolo Progetto	Proponente	Finanziato	Finanziamento	Inizio	Scadenza
2025	PRID-J	Advanced hybrid and targeted lipid-based systems for the delivery of plasmid DNA	Grigoletto Antonella	sì	€ 18.000,00	18/12/2025	31/12/2027
2024	PRID-J	Impairing Importin α 5-Mediated Nrf2 Nuclear Translocation as a Novel Strategy for Treating Chemoresistant Medulloblastoma	Bortolozzi Roberta	sì	€ 16.500,00	17/12/2024	31/12/2026
2024	PRID-J	A proteomic approach to study the dysregulation of proteolytic activity and oxidative state in Inflammatory Bowel Diseases	Franchin Cinzia	sì	€ 16.500,00	17/12/2024	31/12/2026
2024	PRID-J	Development of multicellular 3D in vitro models of metabolic dysfunction-associated steatohepatitis for the advanced screening of active natural compounds and extracts	Gabbia Daniela	sì	€ 16.500,00	17/12/2024	31/12/2026
2024	PRID-J	G protein-coupled receptors roles in oligodendrocyte function	Malfacini Davide	sì	€ 16.500,00	17/12/2024	31/12/2026
2024	PRID-J	Nanomedicine-Driven Immunotherapeutic Strategies in Post-Operative Glioblastoma By Exploiting the STING Pathway	Malfanti Alessio	sì	€ 16.500,00	17/12/2024	31/12/2026
2023	PRID-J	Exploring new pharmaceutical approaches to target the West Nile virus genome	Rigo Riccardo	sì	€ 20.000,00	23/11/2023	31/12/2025
2023	PRID-J	Structure-Based Characterization and Design of mu opioid receptor biased agonists	Salmaso Veronica	sì	€ 20.000,00	23/11/2023	31/12/2025
2021	PRID-J	Development of novel selective melatonin receptors ligands for autism spectrum disorder	Comai Stefano	sì	€ 20.000,00	16/12/2021	15/12/2023
2021	PRID-J	Development of long non-coding RNA-targeting therapeutics for the treatment of melanoma	Groaz Elisabetta	sì	€ 20.000,00	16/12/2021	15/12/2023
2019	PRID-J	Neuro-coagulopathy: role of blood coagulation factor XIIIa in neurodegeneration	Acquasaliente Laura	sì	€ 20.000,00	12/11/2019	11/11/2021
2019	PRID-J	Extracellular vesicles as delivery carriers of oncolytic viruses and therapeutic agents for the treatment of mesothelioma	Garofalo Mariangela	sì	€ 20.000,00	12/11/2019	11/11/2021
2019	PRID-J	New chemical probes for RNA: study of RNA structure by mass spectrometry-based approach	Sosic Alice	sì	€ 20.000,00	12/11/2019	11/11/2021
2018	PRID-J	Interplay between muscle and brain metabolic homeostasis in Hereditary Spastic Paraplegia disease: Drosophila as a tool for new targets and drugs discovery	Orso Genny	sì	€ 20.000,00	06/11/2018	05/11/2020
2017	PRID-J	New modulators of myosin super-relaxed state to contrast obesity and associate diseases	Mattarei Andrea	sì	€ 20.000,00	01/01/2018	31/12/2019
2017	PRID-J	Novel mannose receptor-targeted synthetic polysaccharides for the treatment of arthritis	Mastrotto Francesca	sì	€ 20.000,00	01/01/2018	31/12/2019
2017	PRID-J	Design of novel BCL-2 family inhibitors by using fragment-based drug discovery by NMR approach	Sturlese Mattia	sì	€ 20.000,00	01/01/2018	31/12/2019

Anno	Tipologia	Titolo Progetto	Proponente	Mentore	Finanziamento	Co-finanziamento	Inizio	Termine
2024	ARD-B	Combined therapy based on ANTI-PD-L1 immunoliposomes loaded with vismodegib for skin cancer	Calienni Maria Natalia	Pasut Gianfranco	€ 17.000,00	€ 7.000,00	01/02/2025	31/01/2026
2024	ARD-B	From filaments to condensates: investigating Vimentin-RNA interaction and its potential role in liquid-liquid phase separation	Cozzaglio Marta	Sissi Claudia	€ 17.000,00	€ 7.000,00	01/01/2025	31/12/2025
2023	ARD-B	Vimentin-DNA interaction as a potential novel target for the reprogramming of alternatively polarized tumor-associated macrophages	Ceschi Silvia	Sissi Claudia	€ 19.000,00	€ 10.000,00	rinuncia	
2023	ARD-B	Intestinal neuroimmune responses in multiple sclerosis: the role of microbiota-gut-brain axis	Faggin Sofia	Giron Maria Cecilia	€ 19.000,00	€ 5.000,00	01/12/2023	30/11/2024
2023	ARD-B	Targeting the hyaluronan metabolism as a novel strategy to treat Prostate cancer	Giacomini Isabella	Montopoli Monica	€ 19.000,00	€ 5.000,00	01/02/2024	31/01/2025
2023	ARD-B	Elucidating the Structural basis of the amyloidogenic potential of pathogenic mutations in human transhyretin by limited proteolysis and HDX-MS (StAmP-HDX)	Pierangelini Andrea	De Filippis Vincenzo	€ 19.000,00	€ 5.000,00	rinuncia	
2023	ARD-B	Development of gold nanoparticles as sonosensitizers for targeted Cancer treatment	Daniele Raffaella	Salmaso Stefano	€ 19.000,00	€ 5.000,00	01/12/2023	30/11/2024
2022	ARD-B	Nano-in-macro delivery system for oral administration of biologics	Arpaç Büşra	Salmaso Stefano	€ 38.000,00	€ 10.000,00	01/01/2022	31/12/2024
2022	ARD-B	Innovative fluorescent chemical tools for real time calcium imaging in the Endoplasmic reticulum	De Nadai Andrea	Mattarei Andrea	€ 19.000,00	€ 5.000,00	02/01/2023	01/01/2024
2022	ARD-B	The clock is ticking on cannabidiol and hemp extract: a metabolomic and behavioral preclinical study investigating their effects on tryptophan to serotonin and kynurenine pathways	Sut Stefania	Dall'Acqua Stefano	€ 19.000,00	€ 5.000,00		
2021	ARD-B	Transduceromics studies of the NOP receptor	Malfacini Davide	Calò Girolamo	€ 19.000,00	€ 5.000,00	01/01/2022	31/12/2022
2021	ARD-B	Novel mannose receptor-targeted synthetic polysaccharides for the treatment of arthritis	Ongaro Alberto	Mattarei Andrea	€ 19.000,00	€ 5.000,00	01/02/2022	31/01/2023
2021	ARD-B	A novel biomimetic drug delivery nanovector for the treatment of primary and metastatic pediatric osteosarcoma	Rampado Riccardo	Caliceti Paolo	€ 19.000,00	€ 5.000,00	01/01/2022	31/12/2022
2021	ARD-B	3D models of ovarian cancer cells to shed light on chemoresistance	Hyeraci Mariafrancesca	Dalla Via Lisa	€ 19.000,00	€ 5.000,00		

Anno	Tipologia	Titolo Progetto	Proponente	Mentore	Finanziamento	Co-finanziamento	Inizio	Termine
2021	ARD-B	Evaluation of the synergistic effect (entourage effect) of cannabinoid and terpenoid on in vitro model of dysfunctional intestinal barrier, the anti-inflammatory and antioxidant activities of cannabis extracts and isolated compounds	Sut Stefania	Dall'Acqua Stefano	€ 19.000,00	€ 5.000,00		
2020	ARD-B	Crosstalk between toll-like receptor 4 and catecholaminergic system in inflammatory bowel diseases	Cerantola Silvia	Giron Maria Cecilia	€ 19.000,00	€ 5.000,00	07/01/2021	06/01/2023
2020	ARD-B	Hit-to-lead optimization of a pyrazole-pyrimidine series of new CFTR mutants modulators	Vaccarin Christian	Marzaro Giovanni	€ 19.000,00	€ 5.000,00	07/01/2021	06/01/2022
2020	ARD-B	Liposomes for combination therapy: a new weapon in the battle against EGFR+ breast cancer	Vettorato Elisa	Realdon Nicola	€ 19.000,00	€ 5.000,00	07/01/2021	06/01/2022
2020	ARD-B	Influence of tumor microenvironment in chemotherapy: focus on glutamine metabolism to counteract cisplatin resistance	Cocetta Veronica	Montopoli Monica	€ 19.000,00	€ 5.000,00	15/02/2021	14/02/2022
2020	ARD-B	Metabolism and antitumor activity of novel GSTP1-1 inhibitors for colon cancer therapy	Di Paolo Veronica	Quintieri Luigi	€ 19.000,00	€ 5.000,00	15/03/2021	14/03/2022
2020	ARD-B	Chitosan-based breast cancer-like cultures as tool for in vitro studies on anticancer drugs and electrochemotherapy	Bazzolo Bianca	Conconi Maria Teresa	€ 19.000,00	€ 5.000,00		
2020	ARD-B	The interplay between dopamine, α -synuclein and aromatic L-amino acid decarboxylase: implications in Parkinson disease	Bisello Giovanni	Polverino de Laureto Patrizia	€ 19.000,00	€ 5.000,00		
2020	ARD-B	Frontier spectroscopic techniques to monitor anticancer drug interactions and to identify cancer biomarkers	Hyeraci Mariafrancesca	Dalla Via Lisa	€ 19.000,00	€ 5.000,00		
2020	ARD-B	Natural and synthetic "pungent" alkylamides as new drug candidates	Sut Stefania	Dall'Acqua Stefano	€ 19.000,00	€ 5.000,00		
2019	ARD-B	Polymeric system for manufacturing anticancer vaccines directed to antigen presenting cells	Bellato Federica	Mastrotto Francesca	€ 46.000,00	€ 12.000,00	15/11/2019	14/11/2021
2019	ARD-B	Role of estrogens and gender in the functional regulation of glycolytic proteins in human endothelial cells: implications for novel therapeutic approaches	Boscaro Carlotta	Bolego Chiara	€ 46.000,00	€ 12.000,00	15/11/2019	14/11/2021
2018	ARD-B	MULTI-OMICS APPROACH TO IDENTIFY NOVEL LIPID-RELATED TARGETS AND BIOMARKERS IN CISPLATIN-RESISTANT CANCERS	Catanzaro Daniela	Ragazzi Eugenio	€ 16.000,00	€ 8.000,00	Rinuncia	
2018	ARD-B	NADPH OXIDASE (NOX) INHIBITION: A NOVEL THERAPEUTIC STRATEGY AGAINST LIVER FIBROSIS	Gabbia Daniela	De Martin Sara	€ 16.000,00	€ 8.000,00	01/12/2018	30/11/2019

ASSEGNAZIONI SID 2016-2025

Anno	Tipologia	Titolo Progetto	Proponente	Mentore	Finanziamento	Co-finanziamento	Inizio	Termine
2018	ARD-B	Discovering the interplay between enteric serotonergic pathways and TLR4 signaling in inflammatory bowel disease	Marsilio Ilaria	Giron Maria Cecilia	€ 16.000,00	€ 8.000,00	Ritiro candidatura	
2018	ARD-B	Small molecules as regulators of Protein Phosphatase 2A (PP2A): a novel strategy against cancer	Ribaudò Giovanni	Zagotto Giuseppe	€ 16.000,00	€ 8.000,00	Ritiro candidatura	
2018	ARD-B	Beyond transcription factors: deciphering the role of G-quadruplexes in regulation of EGFR expression	Rigo Riccardo	Sissi Claudia	€ 16.000,00	€ 8.000,00	Ritiro candidatura	
2018	ARD-B	THE ROLE OF EXTRACELLULAR MATRIX COMPONENT FIBRILLIN IN INTESTINAL INFLAMMATION	Schrenk Sandra	Di Liddo Rosa	€ 16.000,00	€ 8.000,00	Ritiro candidatura	
2017	ARD-B	Transglutaminase based approach to prepare antibody drug conjugates	Grigoletto Antonella	Pasut Gianfranco	€ 16.000,00	€ 8.000,00	01/03/2018	28/02/2019
2017	ARD-B	Bacterial infections and thrombosis: non-canonical mechanisms in the activation of the coagulation cascade	Pontarollo Giulia	De Filippis Vincenzo	€ 16.000,00	€ 8.000,00	01/01/2018	31/12/2018